A Q&A with Devora Allon
In this Q&A with Global Competition Review, partner Devora Allon discusses Kirkland's win for Gilead Sciences in a $3.6 billion "pay-for-delay" antitrust case over HIV medications.
In this Q&A with Global Competition Review, partner Devora Allon discusses Kirkland's win for Gilead Sciences in a $3.6 billion "pay-for-delay" antitrust case over HIV medications.
